TY - JOUR T1 - Identification and Evaluation of Serum Protein Biomarkers Which Differentiate Psoriatic from Rheumatoid Arthritis JF - medRxiv DO - 10.1101/2020.06.23.20138552 SP - 2020.06.23.20138552 AU - Angela Mc Ardle AU - Anna Kwasnik AU - Agnes Szenpetery AU - Melissa Jones AU - Belinda Hernandez AU - Micheal Meenagh AU - Andrew Parnell AU - Wilco de Jager AU - Sytze de Roock AU - Oliver FitzGerald AU - Stephen Pennington Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/24/2020.06.23.20138552.abstract N2 - Objectives To identify serum protein biomarkers which might separate early inflammatory arthritis (EIA) patients with psoriatic arthritis (PsA) from those with rheumatoid arthritis (RA) to provide an accurate diagnosis and support appropriate early intervention.Methods In an initial protein discovery phase, the serum proteome of a cohort of patients with PsA and RA was interrogated using unbiased liquid chromatography mass spectrometry (LC-MS/MS) (n=64 patients), a multiplexed antibody assay (Luminex) for 48 proteins (n=64 patients) and an aptamer-based assay (SOMAscan) targeting 1,129 proteins (n=36 patients). Subsequently, analytically validated targeted multiple reaction monitoring (MRM) assays were developed to further evaluate those proteins identified as discriminatory during the discovery. During an initial verification phase, MRM assays were developed to a panel of 150 proteins (by measuring a total of 233 peptides) and used to re-evaluate the discovery cohort (n=60). During a second verification phase, the panel of proteins was expanded to include an additional 23 proteins identified in other proteomic discovery analyses of arthritis patients. The expanded panel was evaluated using a second, independent cohort of PsA and RA patients (n=167).Results Multivariate analysis of the protein discovery data revealed that it was possible to discriminate PsA from RA patients with an area under the curve (AUC) of 0.94 for nLC-MS/MS, 0.69 for Luminex based measurements; 0.73 for SOMAscan analysis. During the initial verification phase, random forest models confirmed that proteins measured by MRM could differentiate PsA and RA patients with an AUC of 0.79 and during the second phase of verification the expanded panel could segregate the two disease groups with an AUC of 0.85.Conclusion We report a serum protein biomarker panel which can separate EIA patients with PsA from those with RA. We suggest that the routine use of such a panel in EIA patients will improve clinical decision making and with continued evaluation and refinement using additional patient cohorts will support the development of a diagnostic test for patients with PsA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the European Commission under the EU FP7 Programme MIAMI (Monitoring innate Immunity in Arthritis and Mucosal Inflammation) project grant (ref. 305266) and Health Research Board grant ref. HRA-HSR-2015-1284. The UCD Conway Institute is funded by the program for research in Third Level Institutions as administered by the Higher Education Authority of Ireland. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by St.Vincents Healthcare Group Ethics and Medical Research Committee and patients were enrolled only after agreeing to participate in the study and having given their informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is included in suppl material. Any additional information is available upon request. ER -